重药控股(000950) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥19,624,282,945.17, a slight increase of 0.02% compared to ¥19,620,276,794.03 in the same period last year[31]. - The net profit attributable to shareholders decreased by 37.99% to ¥102,960,760.48 from ¥166,044,332.35 year-on-year[31]. - The company's total revenue for the first quarter was CNY 19.62 billion, showing a marginal increase of 0.02% compared to CNY 19.62 billion in the previous year[55]. - Net profit for the first quarter was ¥134,762,927.50, down 41.9% from ¥231,764,045.24 in the same period last year[66]. - The company reported a decrease in operating profit to ¥173,133,845.71, down 37.2% from ¥275,798,806.94 year-over-year[66]. - The company’s total comprehensive income for the period was ¥134,762,927.50, down 41.9% from ¥231,764,045.24 in the previous year[66]. - Basic and diluted earnings per share both decreased to ¥0.06 from ¥0.10[72]. Cash Flow - The net cash flow from operating activities showed a net outflow increase of 1.86%, amounting to -¥3,151,359,275.90 compared to -¥3,093,724,213.10 in the previous year[31]. - The company's cash inflow from operating activities for the first quarter was approximately CNY 20.60 billion, an increase from CNY 18.15 billion in the previous year, representing a growth of 13.5%[47]. - The net cash flow from operating activities was a negative CNY 3.15 billion, slightly worse than the negative CNY 3.09 billion recorded in the same period last year, indicating an increase in cash outflow by 1.86%[58]. - The company’s cash flow from financing activities showed a net outflow of ¥416,716,243.92, contrasting with a net inflow of ¥1,330,850,572.46 in the prior year[68]. Assets and Liabilities - The total assets at the end of the reporting period were ¥64,823,403,035.93, reflecting a 2.05% increase from ¥63,523,679,581.87 at the end of the previous year[31]. - Total assets increased to ¥55,807,192,032.72 from ¥54,576,699,681.65, reflecting a growth of approximately 2.25%[64]. - The total liabilities increased to ¥54,313,049,202.80, indicating a rise of approximately 3.5% from the previous period[64]. - Total liabilities rose to ¥49,185,299,480.36 from ¥48,016,315,030.77[70]. - Non-current liabilities increased significantly to ¥6,920,537,273.36 from ¥5,155,886,955.29[70]. Receivables and Inventory - Accounts receivable increased by 7.79% to ¥35,463,920,220.33 from ¥32,900,523,781.08 at the beginning of the year[33]. - Accounts receivable rose to ¥35,463,920,220.33, an increase of 7.8% compared to ¥32,900,523,781.08 at the beginning of the period[64]. - Inventory rose by 4.94% to ¥8,315,792,092.61 compared to ¥7,924,619,690.16 at the beginning of the year[33]. - The company’s inventory increased to ¥8,315,792,092.61, up 4.9% from ¥7,924,619,690.16 at the beginning of the period[64]. Expenses - Financial expenses decreased by 21.51% due to a reduction in total interest-bearing liabilities and financing costs[35]. - Management expenses rose by 16.20% year-on-year, attributed to increased labor costs and depreciation expenses[55]. - Total operating costs increased to ¥19,384,577,382.40 from ¥19,279,821,546.58, with operating costs specifically rising from ¥17,995,584,878.72 to ¥18,103,470,070.75[71]. - Research and development expenses decreased significantly to ¥199,371.05 from ¥1,497,098.60[71]. - Financial expenses decreased to ¥257,833,703.68 from ¥328,473,998.37, with interest expenses dropping from ¥343,628,880.39 to ¥272,482,546.01[71]. Investment - Investment income increased by 24.72% year-on-year, reaching CNY 86.72 million, primarily due to profits from joint ventures[57]. - Investment income increased to ¥86,719,317.32 from ¥69,531,348.46, primarily from joint ventures and associates[71]. - The cash outflow from investment activities was significantly reduced by 233.9%, indicating a shift in investment strategy[58]. - The total cash inflow from investment activities was CNY 17.69 million, down from CNY 109.70 million in the previous year, reflecting a strategic shift in investment focus[58]. Strategic Focus - The company is focusing on digital transformation and expanding its business scope to adapt to changing market demands[8]. - The company received government subsidies amounting to CNY 9.01 million, contributing positively to its financial performance[52].